Biomerica INC

Biomerica, Inc. has successfully closed a private placement of common stock, raising approximately $2.23 million from institutional and individual investors, including key management personnel.

Biomerica, Inc. has entered into a definitive agreement to sell its 6% equity interest in Polish medical firm Diagnosis S.A. to affiliates of its CEO for $500,000.

Biomerica, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including the re-election of directors, executive compensation, auditor ratification, an increase in the stock incentive plan, and a significant increase in authorized common stock.

Biomerica, Inc. announced the appointment of Gary Huff, former CEO of LabCorp Diagnostics, as an independent director, while Dr. Jane Emerson will not seek re-election.

Biomerica, Inc. announced the appointment of Eric B. Chin, a seasoned financial executive, to its Board of Directors and as Chairperson of the Audit Committee, following the resignation of Ms. Cathy Coste.

Biomerica, Inc. will implement a 1-for-8 reverse stock split, effective April 21, 2025, to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement.

Biomerica, Inc. announced its third-quarter fiscal year 2026 financial results, reporting a 12% decrease in net sales compared to the prior year, primarily due to lower contract manufacturing revenue, while also highlighting progress in new product development and a continued focus on liquidity.

Biomerica reported a significant net sales decline and increased operating losses for Q2 2026, raising substantial doubt about its ability to continue as a going concern despite a one-time tax credit.

Biomerica, Inc. reported a net income of $2,000 for Q1 2026, a significant improvement from a loss in the prior year, primarily driven by a one-time Employee Retention Credit refund, despite a 24% drop in net sales.

Biomerica, Inc. reports a net sales increase of 6% for the nine months ended February 28, 2025, but acknowledges substantial doubt about its ability to continue as a going concern due to insufficient cash and strategic growth objectives.

Biomerica's second quarter results show a slight revenue increase but continued losses, prompting cost-cutting measures and a focus on strategic growth.

Biomerica's Q1 2025 results show a slight revenue increase but are overshadowed by rising costs, a workforce reduction, and concerns about the company's ability to continue as a going concern.

Biomerica, Inc. filed an amendment to its 2025 Annual Report, providing updated disclosures on corporate governance, executive compensation, and capital stock structure.

Biomerica, a biomedical technology company, reported a net loss of $4.97 million for fiscal year 2025, alongside a 2% decrease in net sales, while actively pursuing commercialization of its inFoods IBS and hp+detect products and implementing significant cost-cutting measures.

Biomerica's fiscal year 2024 saw a revenue increase driven by non-COVID products, alongside cost-cutting measures due to slower-than-expected product launches.

BIOMERICA Inc. Director Eric Chin was granted 22,500 shares of common stock under the 2024 Stock Incentive Plan, vesting in December 2026.

Biomerica's Chief Financial Officer, Gary Lu, received an award of 40,000 restricted common shares under the company's 2024 Stock Incentive Plan.

Biomerica Inc.'s CEO, Zackary S. Irani, was awarded 52,500 shares of restricted common stock under the 2024 Stock Incentive Plan, vesting over four years.

Biomerica Inc.'s Executive Vice-Chairman, Allen Barbieri, received an award of 30,000 restricted common shares under the 2024 Stock Incentive Plan.

Biomerica Inc. Director David Moatazedi received an award of 20,000 restricted common shares, vesting in December 2026.

Biomerica Inc. Director Gary M. Huff received an award of 20,000 restricted common shares under the company's 2024 Stock Incentive Plan, vesting in December 2026.

Biomerica, Inc. has filed a Definitive Proxy Statement with the SEC, signaling an upcoming shareholder vote.

Biomerica, Inc. filed a DEF 14A proxy statement outlining proposals for its 2025 Annual Meeting, including a significant increase in authorized common stock and amendments to its stock incentive plan.

Biomerica, Inc. is holding its annual meeting on December 13, 2024, seeking stockholder approval for several key proposals, including a reverse stock split, a new stock incentive plan, and amendments to the company's certificate of incorporation.

Wasatch Advisors LP has filed a Schedule 13G with the SEC, indicating that it holds no beneficial ownership in Biomerica Inc. common stock as of December 31, 2024.